Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
Public ClinicalTrials.gov record NCT03626922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without any further standard treatment options.
Study identification
- NCT ID
- NCT03626922
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Pemetrexed Drug
- Oxaliplatin Drug
- Dexamethasone Drug
- Folic Acid Dietary Supplement
- Vitamin B-12 Dietary Supplement
Drug · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2019 (Actual)
- Primary completion
- Oct 31, 2021 (Actual)
- Completion
- Nov 2022 (Estimated)
- Last update posted
- Jun 10, 2022
2019 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UF Health Davis Cancer Pavilion & Shands Medical Plaza | Gainesville | Florida | 32608 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62526 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| Crossroads Cancer Center | Effingham | Illinois | 62401 | — |
| Cancer Care Specialists of Central IL-Swansea | Swansea | Illinois | 062226 | — |
| University of Michigan-Oncology | Ann Arbor | Michigan | 48109 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of Michigan-Brighton Center for Specialty Care | Brighton | Michigan | 48116 | — |
| Minnesota Oncology-Minneapolis | Minneapolis | Minnesota | 55404 | — |
| Hennepin County Medical Center | Minneapolis | Minnesota | 55415 | — |
| HealthPartners Riverside Clinic | Minneapolis | Minnesota | 55454 | — |
| Hubert H. Humphrey Cancer Center | Robbinsdale | Minnesota | 55422 | — |
| Metro Minnesota Community Oncology Research Consortium-MMCORC | Saint Louis Park | Minnesota | 55416 | — |
| Thomas Jefferson University Hospital-Sidney Kimmel Cancer Network | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03626922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2022 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03626922 live on ClinicalTrials.gov.